Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.97 |
| ▸ | CHRNG | P07510 | 1/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | CHRND | Q07001 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Epibatidine SCHEMBL316977 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| (-)-Epibatidine SCHEMBL2500147 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL9070584 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL29390446 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL316978 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL5267259 | 0.97 | CHRNA7 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL5969577 | 0.97 | CHRNA7 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| Homoepibatidine SCHEMBL29711361 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7663147 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL13596272 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005086611-A2 | METHODS OF PRECISE MOLECULAR-LEVEL DETERMINATION OF LIGAND-RECEPTOR INTERACTIONS AND DESIGNING SELECTIVE DRUG COMPOUNDS BASED ON SAID INTERACTIONS | NEURION PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050009103-A1 | Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions | NEURION PHARMACEUTICALS (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009103-A1 | Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions | FSHR, SRPRB, SRPRA | CHRNB2 767/4885CHRNA4 1045/4885CHRNA7 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.